4.2 genetic algorithm (ga) (AUTODOCK GmbH)
90
Structured Review
AUTODOCK GmbH
4.2 genetic algorithm (ga)
4.2 Genetic Algorithm (Ga), supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genetic+algorithm+function+ga/4+2+genetic+algorithm++ga+/us11591288-229-6-6
Average 90 stars, based on 1 article reviews
4.2 Genetic Algorithm (Ga), supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genetic+algorithm+function+ga/4+2+genetic+algorithm++ga+/us11591288-229-6-6
Average 90 stars, based on 1 article reviews
4.2 genetic algorithm (ga) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: X-ray structure of<i>Salmonella typhimurium</i>uridine phosphorylase complexed with 5-fluorouracil and molecular modelling of the complex of 5-fluorouracil with uridine phosphorylase from<i>Vibrio cholerae</i> Article Snippet: A. V. Shubnikov Institute of Crystallography, Russian Academy of Sciences, 59 Leninsky Prospekt, 119333 Moscow, Russian Federation, Shumakov Research Center for Transplantology and Artificial Organs, 1 Shchukinskaya Street, 123182 Moscow, Russian Federation, Blokhin Cancer Center, 24 Kashirskoye Shosse, 115478 Moscow, Russian Federation, University of Hamburg, 85 Notkestrasse, 22603 Hamburg, Germany, and State Research Institute of Genetics and Selection of Industrial Microorganisms, 1 1st Dorozhny Proezd, 117545 Moscow, Russian Federation Article Title: Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. Article Snippet: Chronic myeloid leukemia (CML) is characterized by the presence of p210 which exhibits an abnormal kinase activity.. Selective Abl kinase inhibitors have been successfully established for the treatment of CML.. Despite high rates of clinical response, CML patients can develop resistance against these kinase inhibitors mainly due to point mutations within the Abl protein kinase domain. Article Title: Compositions and methods for treating atherosclerotic cardiovascular disease Article Snippet: Ligand-docking was carried out with the |